sevelamer carbonate winthrop sevelamer carbonate 2.4 g powder for oral suspension sachet
sanofi-aventis australia pty ltd - sevelamer carbonate -
sevelamer hydrochloride winthrop sevelamer hydrochloride 800 mg tablet bottle
sanofi-aventis australia pty ltd - sevelamer hydrochloride -
sevelamer hydrochloride winthrop sevelamer hydrochloride 400 mg tablet bottle
sanofi-aventis australia pty ltd - sevelamer hydrochloride -
sevelamer hydrochloride sanofi sevelamer hydrochloride 800 mg tablet bottle
sanofi-aventis australia pty ltd - sevelamer hydrochloride -
sevelamer hydrochloride sanofi sevelamer hydrochloride 400 mg tablet bottle
sanofi-aventis australia pty ltd - sevelamer hydrochloride -
sevelamer carbonate sanofi sevelamer carbonate 2.4 g powder for oral suspension sachet
sanofi-aventis australia pty ltd - sevelamer carbonate -
sevelamer carbonate sanofi sevelamer carbonate 800 mg tablet bottle
sanofi-aventis australia pty ltd - sevelamer carbonate -
sevelamer carbonate sanofi sevelamer carbonate 1.6 g powder for oral suspension sachet
sanofi-aventis australia pty ltd - sevelamer carbonate -
sevelamer taro 800 mg
taro international ltd, israel - sevelamer carbonate anhydrous - film coated tablets - sevelamer carbonate anhydrous 800 mg - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.
sevelamer taro 800 mg
taro international ltd, israel - sevelamer carbonate anhydrous - film coated tablets - sevelamer carbonate anhydrous 800 mg - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.